TCGA-NC-A5HN-01A-11R-A26W-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 77
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.700
- MYC_TARGETS_V1+0.560
- E2F_TARGETS+0.520
- G2M_CHECKPOINT+0.520
- MTORC1_SIGNALING+0.420
- UNFOLDED_PROTEIN_RESPONSE+0.380
- OXIDATIVE_PHOSPHORYLATION+0.320
- DNA_REPAIR+0.310
- MITOTIC_SPINDLE+0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.220
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- IL6_JAK_STAT3_SIGNALING-0.390
- COMPLEMENT-0.380
- KRAS_SIGNALING_UP-0.380
- ANGIOGENESIS-0.360
- COAGULATION-0.340
- ALLOGRAFT_REJECTION-0.330
- INFLAMMATORY_RESPONSE-0.320
- IL2_STAT5_SIGNALING-0.280
- TGF_BETA_SIGNALING-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-33-AASJ-01A-11R-A405-07 | — | cohortSQ2 | 0.904 |
| 2 | TCGA-77-7139-01A-11R-2045-07 | — | cohortSQ2 | 0.890 |
| 3 | SRR25617920 | — | E | 0.868 |
| 4 | TCGA-63-7023-01A-11R-1949-07 | — | cohortSQ2 | 0.867 |
| 5 | TCGA-58-A46K-01A-11R-A24H-07 | — | cohortSQ2 | 0.864 |
| 6 | TCGA-70-6723-01A-11R-1820-07 | — | cohortSQ2 | 0.864 |
| 7 | TCGA-94-A5I4-01A-11R-A26W-07 | — | cohortSQ2 | 0.864 |
| 8 | SRR6013575 | — | cohortSQ2 | 0.861 |
| 9 | SRR8518179 | — | E | 0.861 |
| 10 | TCGA-77-A5GF-01A-21R-A27Q-07 | — | cohortSQ2 | 0.858 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.700 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.560 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.520 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.420 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.380 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.320 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.220 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.210 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.170 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.130 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.090 | Inavolisib | — uncovered |